Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials

The Oncologist
Mellissa HicksRobert Wesolowski

Abstract

Randomized clinical trials (RCT) that evaluated the addition of lapatinib to trastuzumab plus neoadjuvant chemotherapy (NAC) in patients with HER2-positive, operable breast cancer revealed a questionable improvement in pathologic complete response (pCR) rate. We performed a meta-analysis of prospective RCTs that examined the effect of adding lapatinib to trastuzumab and NAC on pCR rate. PubMed databases and abstracts from the proceedings of the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium were searched for RCTs that compared lapatinib plus trastuzumab and NAC with trastuzumab in combination with NAC and that included pCR as the primary outcome. Our main objective was to estimate the effect of adding lapatinib to trastuzumab plus NAC on pCR rate, defined as no residual invasive cancer in breast and axillary lymph nodes. In total, 1,017 patients with early stage breast cancer from 5 trials were included. Four trials examined the addition of lapatinib to trastuzumab plus NAC; this resulted in statistically significant improvement in pCR, defined as no residual carcinoma in breast and lymph nodes. The pCR rate was 55.76% and 38.36% in the lapatinib plus trastuzumab and the trastuzumab plus NAC a...Continue Reading

References

Mar 1, 1985·Progress in Cardiovascular Diseases·S YusufP Sleight
Feb 1, 1996·Controlled Clinical Trials·A R JadadH J McQuay
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Apr 30, 2004·Statistics in Medicine·Michael J SweetingPaul C Lambert
Dec 17, 2008·Current Oncology Reports·Robert Wesolowski, Georg Thomas Budd
Jul 28, 2009·Journal of Clinical Epidemiology·David MoherUNKNOWN PRISMA Group
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaheenah DawoodSharon H Giordano
Jan 20, 2012·The Lancet Oncology·Michael UntchUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study Group
Mar 7, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Erin M Olson
Apr 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina GuarneriPierfranco Conte
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kimberly L BlackwellJoyce O'Shaughnessy

❮ Previous
Next ❯

Citations

May 18, 2016·Clinical & Experimental Metastasis·A TachtsidisC M Saunders
Aug 16, 2016·The Breast : Official Journal of the European Society of Mastology·Michael J DuffyJohn Crown
Dec 25, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W Sledge
Jul 1, 2017·Future Oncology·Mathew A Cherian, Cynthia X Ma
Feb 20, 2018·Molecular Cancer·Qinlian JiaoYun-Shan Wang
Dec 7, 2018·Expert Review of Anticancer Therapy·Carlos Martínez-PérezJ Michael Dixon
Jan 29, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Larissa A KordeDawn L Hershman
Jun 6, 2017·Biochemical and Biophysical Research Communications·Yun YangZhiwei Feng

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.